Medtronic Announces Second Quarter Fiscal Year 2025 Financial Results

Details

The company announced worldwide revenue of $8.403 billion, a 5.3% increase from the prior year. GAAP diluted earnings per share (EPS) was $0.99, and non-GAAP diluted EPS was $1.26. The company raised its fiscal year 2025 organic revenue growth and non-GAAP EPS guidance. Key highlights include revenue growth in its Cardiovascular, Neuroscience, and Diabetes segments. Additionally, Medtronic released its FY24 Impact Report, highlighting sustainability achievements.

Items reported

Exhibits (1)

About Medtronic plc

Medtronic plc is a leading global healthcare technology company that designs, manufactures, and sells innovative medical devices and therapies used in various medical procedures. The primary function of Medtronic is to improve healthcare outcomes by providing advanced therapeutic solutions. Its extensive product portfolio includes cardiac and vascular devices, diabetes-related products, minimally invasive therapies, and neurosurgical technologies. Medtronic plays a vital role in the medical device industry, catering to cardiovascular treatment, advanced diabetes management, spinal and musculoskeletal therapy, and more. Notably, the company is renowned for its pacemaker technology and is a pivotal player in cardiac care. The company's innovations significantly impact the healthcare sector by enhancing the quality of life for patients worldwide and improving the effectiveness of medical treatments. As a key player in the medical device market, Medtronic is instrumental in setting industry standards and advancing medical technology through continuous research and development. Founded in 1949 and headquartered in Dublin, Ireland, Medtronic's global presence underscores its substantial contribution to the healthcare industry across various continents.